PINK1

PTEN induced kinase 1, the group of MicroRNA protein coding host genes

Basic information

Region (hg38): 1:20633458-20651511

Previous symbols: [ "PARK6" ]

Links

ENSG00000158828NCBI:65018OMIM:608309HGNC:14581Uniprot:Q9BXM7AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • autosomal recessive early-onset Parkinson disease 6 (Strong), mode of inheritance: AR
  • autosomal recessive early-onset Parkinson disease 6 (Definitive), mode of inheritance: AR
  • young-onset Parkinson disease (Supportive), mode of inheritance: AR
  • autosomal recessive early-onset Parkinson disease 6 (Strong), mode of inheritance: AR
  • Parkinson disease (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Parkinson disease 6, early onsetARNeurologicResponse to levodopa has been documentedNeurologic15505170; 15349870; 15087508; 15955954; 15970950; 16969854; 17030667; 16769864; 16966503; 16632486; 18685134; 18541801; 21784538; 22581678; 22956510
Heterozygotes may display more subtle signs of disease, and have been described as susceptibility alleles

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the PINK1 gene.

  • Autosomal recessive early-onset Parkinson disease 6 (18 variants)
  • not provided (3 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the PINK1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
7
clinvar
53
clinvar
3
clinvar
63
missense
1
clinvar
4
clinvar
132
clinvar
6
clinvar
2
clinvar
145
nonsense
8
clinvar
2
clinvar
1
clinvar
11
start loss
0
frameshift
7
clinvar
2
clinvar
1
clinvar
10
inframe indel
2
clinvar
2
splice donor/acceptor (+/-2bp)
2
clinvar
3
clinvar
5
splice region
9
5
2
16
non coding
26
clinvar
41
clinvar
28
clinvar
95
Total 18 11 169 100 33

Highest pathogenic variant AF is 0.0000525

Variants in PINK1

This is a list of pathogenic ClinVar variants found in the PINK1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
1-20633561-C-T Autosomal recessive early-onset Parkinson disease 6 Pathogenic (Sep 16, 2022)661098
1-20633572-C-T Autosomal recessive early-onset Parkinson disease 6 Likely benign (Feb 10, 2023)2739036
1-20633573-C-G Autosomal recessive early-onset Parkinson disease 6 Uncertain significance (Dec 02, 2021)1356897
1-20633579-C-A Uncertain significance (Sep 13, 2016)291205
1-20633595-C-T Autosomal recessive early-onset Parkinson disease 6 • Inborn genetic diseases Conflicting classifications of pathogenicity (Aug 02, 2023)1374264
1-20633611-C-T Autosomal recessive early-onset Parkinson disease 6 Likely benign (Nov 22, 2023)2740590
1-20633613-C-T Autosomal recessive early-onset Parkinson disease 6 Uncertain significance (Jan 17, 2022)2043218
1-20633615-G-A not specified • Autosomal recessive early-onset Parkinson disease 6 • PINK1-related disorder Conflicting classifications of pathogenicity (Oct 18, 2021)447940
1-20633617-C-G Autosomal recessive early-onset Parkinson disease 6 Likely benign (Mar 03, 2023)1602646
1-20633622-CCGGCCGGGCCTACGGCTTGGGG-C Autosomal recessive early-onset Parkinson disease 6 Pathogenic (Aug 09, 2022)1454290
1-20633624-G-C Autosomal recessive early-onset Parkinson disease 6 Uncertain significance (Sep 09, 2020)1016581
1-20633633-T-G Inborn genetic diseases Uncertain significance (Jun 18, 2021)2229752
1-20633636-G-A Autosomal recessive early-onset Parkinson disease 6 Likely benign (Sep 19, 2023)2767231
1-20633636-G-C Autosomal recessive early-onset Parkinson disease 6 Conflicting classifications of pathogenicity (Dec 10, 2023)294997
1-20633639-T-G Inborn genetic diseases Uncertain significance (Jun 18, 2021)2233309
1-20633649-C-G Autosomal recessive early-onset Parkinson disease 6 Uncertain significance (Aug 09, 2022)1399865
1-20633660-G-A Inborn genetic diseases Uncertain significance (Feb 21, 2024)2573958
1-20633661-C-T Autosomal recessive early-onset Parkinson disease 6 Uncertain significance (Aug 24, 2023)2724783
1-20633664-G-T Autosomal recessive early-onset Parkinson disease 6 Uncertain significance (Oct 13, 2022)1407492
1-20633672-C-T Autosomal recessive early-onset Parkinson disease 6 Uncertain significance (Jul 10, 2019)939290
1-20633677-G-A Autosomal recessive early-onset Parkinson disease 6 Likely benign (Feb 12, 2022)1951123
1-20633687-G-C Autosomal recessive early-onset Parkinson disease 6 • See cases • Inborn genetic diseases Uncertain significance (May 16, 2022)1675350
1-20633689-C-G Autosomal recessive early-onset Parkinson disease 6 Likely benign (Dec 12, 2023)1510457
1-20633701-A-G Autosomal recessive early-onset Parkinson disease 6 Likely benign (Aug 03, 2023)703431
1-20633703-C-T Uncertain significance (Jul 17, 2018)586235

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
PINK1protein_codingprotein_codingENST00000321556 818057
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.87e-100.39712563001181257480.000469
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.1293083140.9800.00001913651
Missense in Polyphen106122.220.867281429
Synonymous-1.751661401.190.000009261296
Loss of Function1.051823.50.7660.00000137253

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.001170.00117
Ashkenazi Jewish0.00009920.0000992
East Asian0.001030.00103
Finnish0.0001850.000185
European (Non-Finnish)0.0003530.000352
Middle Eastern0.001030.00103
South Asian0.0003940.000392
Other0.0009800.000978

dbNSFP

Source: dbNSFP

Function
FUNCTION: Protects against mitochondrial dysfunction during cellular stress by phosphorylating mitochondrial proteins. Involved in the clearance of damaged mitochondria via selective autophagy (mitophagy) by mediating activation and translocation of PRKN (PubMed:14607334, PubMed:15087508, PubMed:19229105, PubMed:19966284, PubMed:20404107, PubMed:20798600, PubMed:23620051, PubMed:23754282, PubMed:23933751, PubMed:24660806, PubMed:24751536, PubMed:24784582, PubMed:24896179, PubMed:25527291). Targets PRKN to dysfunctional depolarized mitochondria through the phosphorylation of MFN2 (PubMed:23620051). Activates PRKN in 2 steps: (1) by mediating phosphorylation at 'Ser-65' of PRKN and (2) mediating phosphorylation of ubiquitin, converting PRKN to its fully-active form (PubMed:24660806, PubMed:24751536, PubMed:24784582, PubMed:25527291). Required for ubiquinone reduction by mitochondrial complex I by mediating phosphorylation of complex I subunit NDUFA10 (By similarity). {ECO:0000250|UniProtKB:Q99MQ3, ECO:0000269|PubMed:14607334, ECO:0000269|PubMed:15087508, ECO:0000269|PubMed:19229105, ECO:0000269|PubMed:19966284, ECO:0000269|PubMed:20404107, ECO:0000269|PubMed:20798600, ECO:0000269|PubMed:23620051, ECO:0000269|PubMed:23754282, ECO:0000269|PubMed:23933751, ECO:0000269|PubMed:24660806, ECO:0000269|PubMed:24751536, ECO:0000269|PubMed:24784582, ECO:0000269|PubMed:24896179, ECO:0000269|PubMed:25527291}.;
Disease
DISEASE: Parkinson disease 6 (PARK6) [MIM:605909]: An early-onset form of Parkinson disease, a neurodegenerative disorder characterized by parkinsonian signs such as rigidity, resting tremor and bradykinesia. A subset of patients manifest additional symptoms including hyperreflexia, autonomic instability, dementia and psychiatric disturbances. Symptoms show diurnal fluctuation and can improve after sleep. PARK6 pathogenesis involves respiratory complex I deficiency causing mitochondrial depolarization and dysfunction. Inheritance is autosomal recessive. {ECO:0000269|PubMed:15087508, ECO:0000269|PubMed:15349860, ECO:0000269|PubMed:15349870, ECO:0000269|PubMed:15505171, ECO:0000269|PubMed:15596610, ECO:0000269|PubMed:15955953, ECO:0000269|PubMed:15970950, ECO:0000269|PubMed:16009891, ECO:0000269|PubMed:16207217, ECO:0000269|PubMed:16207731, ECO:0000269|PubMed:16257123, ECO:0000269|PubMed:16401616, ECO:0000269|PubMed:16482571, ECO:0000269|PubMed:16632486, ECO:0000269|PubMed:16966503, ECO:0000269|PubMed:17030667, ECO:0000269|PubMed:18286320, ECO:0000269|PubMed:19229105, ECO:0000269|PubMed:20798600, ECO:0000269|PubMed:22043288, ECO:0000269|PubMed:22956510, ECO:0000269|PubMed:24652937, ECO:0000269|PubMed:24784582}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Mitophagy - animal - Homo sapiens (human);Parkinson,s disease - Homo sapiens (human);Parkinsons Disease Pathway;Pink/Parkin Mediated Mitophagy;Mitophagy (Consensus)

Recessive Scores

pRec
0.176

Intolerance Scores

loftool
0.788
rvis_EVS
-0.46
rvis_percentile_EVS
23.63

Haploinsufficiency Scores

pHI
0.143
hipred
Y
hipred_score
0.564
ghis
0.507

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.988

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumHigh
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Pink1
Phenotype
taste/olfaction phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; immune system phenotype;

Zebrafish Information Network

Gene name
pink1
Affected structure
dopaminergic neuron
Phenotype tag
abnormal
Phenotype quality
decreased amount

Gene ontology

Biological process
autophagy of mitochondrion;positive regulation of protein phosphorylation;regulation of oxidative phosphorylation;response to ischemia;protein phosphorylation;ubiquitin-dependent protein catabolic process;response to oxidative stress;mitochondrion organization;regulation of hydrogen peroxide metabolic process;negative regulation of gene expression;regulation of mitochondrion organization;positive regulation of peptidase activity;macroautophagy;positive regulation of macroautophagy;negative regulation of macroautophagy;protein ubiquitination;peptidyl-serine phosphorylation;respiratory electron transport chain;regulation of protein ubiquitination;positive regulation of protein ubiquitination;activation of protein kinase B activity;positive regulation of synaptic transmission, dopaminergic;positive regulation of peptidyl-serine phosphorylation;positive regulation of dopamine secretion;cellular response to oxidative stress;positive regulation of protein dephosphorylation;intracellular signal transduction;peptidyl-serine autophosphorylation;TORC2 signaling;positive regulation of I-kappaB kinase/NF-kappaB signaling;regulation of protein complex assembly;negative regulation of neuron apoptotic process;positive regulation of translation;negative regulation of JNK cascade;protein stabilization;positive regulation of DNA-binding transcription factor activity;positive regulation of ubiquitin-protein transferase activity;regulation of mitochondrial membrane potential;positive regulation of protein kinase B signaling;regulation of proteasomal protein catabolic process;cellular response to hypoxia;establishment of protein localization to mitochondrion;maintenance of protein location in mitochondrion;positive regulation of mitochondrial fission;positive regulation of release of cytochrome c from mitochondria;negative regulation of mitochondrial fission;cellular response to toxic substance;positive regulation of mitophagy in response to mitochondrial depolarization;mitochondrion to lysosome transport;regulation of cellular response to oxidative stress;positive regulation of histone deacetylase activity;regulation of synaptic vesicle transport;negative regulation of autophagosome assembly;positive regulation of mitochondrial electron transport, NADH to ubiquinone;regulation of autophagy of mitochondrion;negative regulation of autophagy of mitochondrion;negative regulation of oxidative stress-induced cell death;negative regulation of oxidative stress-induced neuron death;regulation of protein targeting to mitochondrion;negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway;negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway;negative regulation of intrinsic apoptotic signaling pathway in response to hydrogen peroxide;positive regulation of cristae formation;positive regulation of protein targeting to mitochondrion;positive regulation of free ubiquitin chain polymerization;positive regulation of NMDA glutamate receptor activity;cellular response to hydrogen sulfide;regulation of reactive oxygen species metabolic process;negative regulation of reactive oxygen species metabolic process;positive regulation of ATP biosynthetic process;negative regulation of intrinsic apoptotic signaling pathway
Cellular component
ubiquitin ligase complex;chromatin;nucleus;cytoplasm;mitochondrion;mitochondrial outer membrane;mitochondrial outer membrane translocase complex;mitochondrial inner membrane;mitochondrial intermembrane space;cytosol;cytoskeleton;membrane;axon;growth cone;integral component of mitochondrial outer membrane;TORC2 complex;cell body;perinuclear region of cytoplasm;Lewy body;astrocyte projection
Molecular function
magnesium ion binding;protease binding;protein kinase activity;protein serine/threonine kinase activity;protein binding;ATP binding;calcium-dependent protein kinase activity;kinase activity;peptidase activator activity;ubiquitin protein ligase binding;protein kinase B binding;C3HC4-type RING finger domain binding